Sarah Howell, PhD
On The Move: Who’s Going Where In Biopharma And Medtech Start-Ups
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
More from Archive
More from Scrip
• By
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
• By
With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.
• By
The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.